Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.49 |
| ▸ | CCKBR | P32239 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489050 | 0.90 | PDE2A (0.58) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL5360424 | 0.85 | PDE2A (0.66) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| Dimethylamine SCHEMBL5493029 | 0.82 | PDE2A (0.65) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL4709075 | 0.81 | PDE2A (0.61) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL5496998 | 0.81 | PDE2A (0.67) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL5488783 | 0.80 | PDE2A (0.68) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL4709486 | 0.80 | PDE2A (0.48) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL5486258 | 0.79 | PDE2A (0.81) | PDE2AGABRA1GABRA5GABRA2GABRB2 | |
| SCHEMBL31695994 | 0.79 | GABRA1 (0.73) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL5490269 | 0.79 | PDE2A (0.64) | PDE2AGABRA1GABRA5GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | PDE2A 7/4885GABRA1 92/4885GABRA5 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.